The performance maintains rapid growth, Grand Pharmaceuticals (00512) expects that the comprehensive net profit attributable to shareholders in the interim period will increase by not less than 50% year-on-year

　　Yuanda Pharmaceutical(00512) announced that in the first half of 2021, the company’sNet profitThe year-on-year growth is not less than 50%, and the unaudited consolidated net profit attributable to company owners for the same period in 2020 is approximately HK$718.5 million.

The board believes thatPerformanceThe reasons for maintaining good growth (among other factors) are mainly: the group continues to optimize its profit structure, continues to promote the group’s innovation and barrier drug development strategy, and strives to promote the sales of innovative high-barrier and high-margin products, resulting in overall sales revenue compared with last year The same as expected growth of not less than 40%; and held listingsCompany investmentChanges in the fair value of the portfolio push up investment returns. In summary, while the group is committed to investing in research and development, the group’s net profit level has maintained sustained and rapid growth.

Since the beginning of the year,Yuanda PharmaceuticalA number of innovative products have been deployed in the fields of anti-tumor, cardio-cerebral vascular precision intervention, and traditional superior ophthalmology, continuously consolidating the group’s pipeline layout in the field of technological innovation, and adding new impetus to the group’s performance growth. at the same time,Yuanda PharmaceuticalA number of innovative products under research have also made progress in research and development in the first half of the year, and the group’s overall research and development process continues to improve.It is understood that Broad Pharmaceutical’s interim resultsannouncementIt will be released in mid-August and will present the group’s comprehensive financial results for the first half of the year.

(Source: Zhitong Finance Network)

Article source: Zhitong Finance Network

Editor in charge: DF398

Original title: Performance maintains rapid growth, Grand Pharmaceuticals (00512) expects that the comprehensive net profit attributable to shareholders in the interim period will increase by not less than 50% year-on-year